WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Minang Turakhia Biography and Net Worth

Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation of iRhythm Technologies

Mintu Turakhia MD MS has served as our Chief Medical Officer and Chief Scientific Officer since June 2022 and as our Executive Vice President, Product Innovation since April 2023. Dr. Turakhia has served as a Professor of Medicine (on leave) at the Stanford University School of Medicine since August 2008. From August 2008 to June 2022, Dr. Turakhia served as Chief, Cardiac Electrophysiology at VA Palo Alto Health Care System, where he still practices and performs catheter ablation and device implantation.

Dr. Turakhia holds a B.S. in Molecular Biology and Computer Science from the University of California, Berkeley, and received his M.D. from the University of California, San Francisco. He also holds a M.S. in Clinical Research from University of California, San Francisco and received clinical training at Harvard’s Brigham & Women’s Hospital and the University of California, San Francisco.

What is Minang Turakhia's net worth?: The estimated net worth of Minang Turakhia is at least $2.46 million as of July 2nd, 2024. Dr. Turakhia owns 27,255 shares of iRhythm Technologies stock worth more than $2,463,579 as of December 22nd. This net worth evaluation does not reflect any other assets that Dr. Turakhia may own. Additionally, Dr. Turakhia receives an annual salary of $749,180.00 as Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation at iRhythm Technologies. Learn More about Minang Turakhia's net worth.
How old is Minang Turakhia?: Dr. Turakhia is currently 50 years old. There are 7 older executives and no younger executives at iRhythm Technologies. The oldest executive at iRhythm Technologies is Mr. Marc Rosenbaum, Senior VP of Finance & Chief Accounting Officer, who is 52 years old. Learn More on Minang Turakhia's age.
What is Minang Turakhia's salary?: As the Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation of iRhythm Technologies, Inc., Dr. Turakhia earns $749,180.00 per year. There are 3 executives that earn more than Dr. Turakhia. The highest earning executive at iRhythm Technologies is Mr. Quentin S. Blackford, President, CEO & Director, who commands a salary of $1,420,000.00 per year. Learn More on Minang Turakhia's salary.
How do I contact Minang Turakhia?: The corporate mailing address for Dr. Turakhia and other iRhythm Technologies executives is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. iRhythm Technologies can also be reached via phone at (415) 632-5700 and via email at [email protected]. Learn More on Minang Turakhia's contact information.
Has Minang Turakhia been buying or selling shares of iRhythm Technologies?: Minang Turakhia has not been actively trading shares of iRhythm Technologies during the last ninety days. Most recently, Minang Turakhia sold 1,404 shares of the business's stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $105.65, for a transaction totalling $148,332.60. Following the completion of the sale, the chief marketing officer now directly owns 27,255 shares of the company's stock, valued at $2,879,490.75. Learn More on Minang Turakhia's trading history.
Who are iRhythm Technologies' active insiders?: iRhythm Technologies' insider roster includes C. Bairey Merz (Director), Quentin Blackford (CEO), Mark Day (EVP), Douglas Devine (CFO), Patrick Murphy (EVP), Chad Patterson (Chief Commercial Officer), Sumi Shrishrimal (EVP, Chief Risk Officer), Mervin Smith (EVP of Business Operations), Minang Turakhia (Chief Medical Officer, Chief Scientific Officer and EVP, Product Innovation), David Vort (EVP), and Daniel Wilson (EVP). Learn More on iRhythm Technologies' active insiders.
Are insiders buying or selling shares of iRhythm Technologies?: In the last year, iRhythm Technologies insiders bought shares 2 times. They purchased a total of 6,944 shares worth more than $521,860.64. In the last year, insiders at the sold shares 13 times. They sold a total of 69,024 shares worth more than $7,151,438.22. The most recent insider tranaction occured on December, 2nd when insider Patrick Michael Murphy sold 2,492 shares worth more than $214,037.88. Insiders at iRhythm Technologies own 0.7% of the company. Learn More about insider trades at iRhythm Technologies.
Information on this page was last updated on 12/2/2024.

Minang Turakhia Insider Trading History at iRhythm Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/2/2024	Sell	1,404	$105.65	$148,332.60	27,255

Minang Turakhia Buying and Selling Activity at iRhythm Technologies

iRhythm Technologies Company Overview

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $90.39

$85.29

$91.22

50 Day Range

MA: $80.38

$57.94

$91.45

2 Week Range

Now: $90.39

$55.92

$124.11

Volume

506,936 shs

Average Volume

465,130 shs

Market Capitalization

$2.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

WARNING: “Buffett Indicator” flashing for first time in 50 years

From Behind the Markets | Ad

Take these 4 steps today to protect your retirement NOW

Minang Turakhia Biography and Net Worth

What is Minang Turakhia's net worth?

How old is Minang Turakhia?

What is Minang Turakhia's salary?

How do I contact Minang Turakhia?

Has Minang Turakhia been buying or selling shares of iRhythm Technologies?

Who are iRhythm Technologies' active insiders?

Are insiders buying or selling shares of iRhythm Technologies?